Abstract LB123: Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib

MLA

Yasir Y. Elamin, et al. “Abstract LB123: Poorer Outcomes in EGFR L858R-Driven NSCLC Treated with Osimertinib May Be Addressed with Novel Combination of BLU-945 and Osimertinib.” Cancer Research, vol. 83, Apr. 2023, p. LB123. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4f5b1a531de5242226cad16c1c567c78&authtype=sso&custid=ns315887.

APA

Yasir Y. Elamin, Tyler Rouskin-Faust, Nicole Zhang, Teresa Green, Aditya Dhande, Brenton G. Mar, John V. Heymach, & Chiara Conti. (2023). Abstract LB123: Poorer outcomes in EGFR L858R-driven NSCLC treated with osimertinib may be addressed with novel combination of BLU-945 and osimertinib. Cancer Research, 83, LB123.

Chicago

Yasir Y. Elamin, Tyler Rouskin-Faust, Nicole Zhang, Teresa Green, Aditya Dhande, Brenton G. Mar, John V. Heymach, and Chiara Conti. 2023. “Abstract LB123: Poorer Outcomes in EGFR L858R-Driven NSCLC Treated with Osimertinib May Be Addressed with Novel Combination of BLU-945 and Osimertinib.” Cancer Research 83 (April): LB123. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........4f5b1a531de5242226cad16c1c567c78&authtype=sso&custid=ns315887.